Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone

Author:

Locher H H1,Schlunegger H1,Hartman P G1,Angehrn P1,Then R L1

Affiliation:

1. Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Abstract

Epiroprim (EPM; Ro 11-8958) is a new selective inhibitor of microbial dihydrofolate reductase. EPM displayed excellent activity against staphylococci, enterococci, pneumococci, and streptococci which was considerably better than that of trimethoprim (TMP). EPM was also active against TMP-resistant strains, although the MICs were still relatively high. Its combination with dapsone (DDS) was synergistic and showed as in vitro activity superior to that of the TMP combination with sulfamethoxazole (SMZ). The EPM-DDS (ratio, 1:19) combination inhibited more than 90% of all important gram-positive pathogens at a concentration of 2 + 38 micrograms/ml. Only a few highly TMP-resistant staphylococci and enterococci were not inhibited. EPM was also more active than TMP against Moraxella catarrhalis, Neisseria meningitidis, and Bacteroides spp., but it was less active than TMP against all other gram-negative bacteria tested. Atypical mycobacteria were poorly susceptible to EPM, but the combination with DDS was synergistic and active at concentrations most probably achievable in biological fluids (MICs from 0.25 +/- 4.75 to 4 + 76 micrograms/ml). EPM and the EPM-DDS combination were also highly active against experimental staphylococcal infections in a mouse septicemia model. The combination EPM-DDS has previously been shown to exhibit activity in Pneumocystis carinii and Toxoplasma models and, as shown in the present study, also shows good activity against a broad range of bacteria including many strains resistant to TMP and TMP-SMZ.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference14 articles.

1. Antibacterial properties of Ro 40-6890. a broad-spectrum cephalosporin, and its novel orally absorbable ester;Angehrn P.;Ro,1992

2. Brun-Pascaud M. C. F. Derovin and P. M. Girard. 1995. Experimental evaluation of epiroprim alone or combined with dapsone in dual pneumocystosis and toxoplasmosis infection in a rat model abstr. B53 p. 35. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.

3. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor alone and in combination with dapsone against Toxoplasma gondii. Antimicrob;Chang H. R.;Agents Chemother,1994

4. Prevention and treatment of opportunistic infections;Dubé M. P.;Curr. Opin. Infect. Dis.,1993

5. Eliopoulos G. M. and R. C. Moellering. 1992. Antimicrobial combinations p. 432-492. In V. Lorian (ed.) Antibiotics in laboratory medicine 3rd ed. The Williams & Wilkins Co. Baltimore.

Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3